Lytus Technologies Holdings PTV. Ltd. LYT
0.10 USD 0.00 (+0.00%)
At closeJun 17, 2025, 4:00 PM EDT
0.0982 Day range 0.1098
0.94 52-week range 18.62
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 2.22M
- Revenue (ttm)
- 21.36M
- Profit margin
- 1.35%
- EPS (ttm)
- 0.30
- Shares out
- 1.86M
- P/E ratio
- 3.97
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 54.48M
- Avg volume
- 955.20K
- Open
- 0.1098
- Previous close
- 0.0982
- Day's range
- 0.0982 – 0.1098
- 52-week range
- 0.94 – 18.62
- Beta
- 1.84
No chart data for this range yet.
Key statistics
- Enterprise value
- 3.14M
- PEG ratio
- 0.00
- Price / sales
- 0.10
- Price / book
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 26.70%
- Free cash flow
- -4.37M
- Total cash
- 4.47M
- Total debt
- 2.63M
- Return on equity
- 4.89%
- Short % of float
- 3.90%
- 50-day average
- 1.63
- 200-day average
- 2.50
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
LYT Revenue — annual 23.00M
LYT Net income — annual 287.67K
LYT EPS — annual 0.30
About Lytus Technologies Holdings PTV. Ltd.
Lytus Technologies Holdings PTV. Ltd. operates as a platform services company in India. It operates in two segments, Cable Services and Telemedicine Services. The company engages in the distribution of linear content streaming/telecasting services; and development of telemedicine and fintech products. Lytus Technologies Holdings PTV. Ltd. was incorporated in 2020 and is based in Mumbai, India.
- Sector
- Technology
- Industry
- Software - Application
- Country
- India
- Website
- lytuscorp.com
News
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis 
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis 
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome 
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF 
12 Communication Services Stocks Moving In Friday's After-Market Session 
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall 
12 Communication Services Stocks Moving In Wednesday's After-Market Session - 12 Communication Services Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on LYT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.63% | 11,813 | 14.06K | Sep 29, 2024 |
| Lazard Asset Management LLC | 0.03% | 637 | 758 | Sep 29, 2024 |
| Aspire Private Capital, LLC | 0.00% | 14 | 16 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.04% | 679 | 808 | Sep 29, 2024 |